PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2032 Views
-
Last post by NHE
-
- 0 Replies
- 944 Views
-
Last post by NHE
-
- 0 Replies
- 9878 Views
-
Last post by NHE
-
- 0 Replies
- 1925 Views
-
Last post by Firidion
-
- 1 Replies
- 1332 Views
-
Last post by vesta
-
- 0 Replies
- 1968 Views
-
Last post by frodo
-
- 0 Replies
- 1887 Views
-
Last post by NHE
-
- 0 Replies
- 1477 Views
-
Last post by NHE
-
- 4 Replies
- 2387 Views
-
Last post by JohnC777